Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

OptimizeRx (OPRX) Shares Outstanding (Weighted Average) (2016 - 2025)

OptimizeRx (OPRX) has disclosed Shares Outstanding (Weighted Average) for 16 consecutive years, with $18.6 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 1.43% to $18.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $18.6 million through Dec 2025, up 1.43% year-over-year, with the annual reading at $18.6 million for FY2025, 1.43% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $18.6 million in Q4 2025 for OptimizeRx, roughly flat from $18.5 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $18.6 million in Q4 2025 to a low of $16.1 million in Q1 2021.
  • Historically, Shares Outstanding (Weighted Average) has averaged $17.8 million across 5 years, with a median of $17.9 million in 2022.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): rose 19.78% in 2021 and later fell 6.24% in 2023.
  • Year by year, Shares Outstanding (Weighted Average) stood at $17.2 million in 2021, then increased by 3.23% to $17.8 million in 2022, then decreased by 3.71% to $17.1 million in 2023, then rose by 6.82% to $18.3 million in 2024, then increased by 1.43% to $18.6 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for OPRX at $18.6 million in Q4 2025, $18.5 million in Q3 2025, and $18.5 million in Q2 2025.